Table I.
Baseline clinical characteristics according to the levels of BNP.
| Characteristics | Patients with BNP ≤100 pg/ml (n=900) | Patients with BNP >100 pg/ml (n=515) | P-value |
|---|---|---|---|
| Age, years (range) | 63 (50.0–76.0) | 70 (56.4–83.6) | <0.05 |
| Male gender, n (%) | 513/900 (57.00) | 277/515 (53.79) | 0.242 |
| Mortality, n (%) | 7 (0.77) | 24 (4.66) | <0.05 |
| Readmission, n (%) | 136 (15.11) | 169 (32.82) | <0.05 |
| Key events, n (%) | 143 (15.89) | 193 (37.47) | <0.05 |
| Systolic dysfunction, n (%) | 18/841 (2.14) | 105/470 (22.34) | <0.05 |
| Non-systolic dysfunction, n (%) | 163/841 (19.38) | 232/470 (49.36) | <0.05 |
| Hypertension, n (%) | 638 (70.89) | 315 (61.16) | <0.05 |
| Diabetes, n (%) | 176 (19.55) | 115 (22.33) | 0.214 |
| Dyslipidemia, n (%) | 477 (53.00) | 145 (28.15) | <0.05 |
| Renal dysfunction, n (%) | 31 (3.44) | 84 (16.31) | <0.05 |
| Myocardial infarction, n (%) | 96 (10.67) | 94 (18.25) | <0.05 |
| Medication, n (%) | |||
| β-blockers | 480 (53.33) | 250 (48.54) | 0.083 |
| Calcium antagonists | 413 (45.89) | 186 (36.12) | <0.05 |
| Diuretics | 230 (25.56) | 378 (73.40) | <0.05 |
| Nitrates | 386 (42.89) | 230 (44.66) | 0.518 |
| Antiplatelet agents | 713 (79.22) | 379 (73.59) | 0.015 |
| Statins | 325 (36.11) | 135 (26.21) | <0.05 |
| ACEIs or ARBs | 638 (70.88) | 375 (72.82) | 0.439 |
| ACEIs | 302 (33.56) | 187 (36.31) | 0.294 |
| ARBs | 336 (37.33) | 188 (36.50) | 0.756 |
BNP, brain natriuretic peptide; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers.